After generating over 10 million social media impressions with the launch of its text-to-3D model app, Adam has raised a $4.1 ...

As Shiba Inu (SHIB) continues to struggle under pressure close to important support levels, smart investors are considering ...

Earlier this month, I sat down for a Pulse Check with Dr. Patrick O’Shaughnessy, president and CEO of Catholic Health: a six ...

For months, Illinois transit leaders warned of a doomsday scenario that would hobble the region’s mass transit systems. That ...

Intellia Therapeutics, Inc. is rated Hold due to uncertainty from dosing pause in its MAGNITUDE program for ATTR. Learn more ...

When America embarked on the journey to build the Arsenal of Democracy in World War II, President Roosevelt had a simple ...

Imagine you’ve just been told you have cancer and all of the emotions and questions that would race through your mind. Next ...

The president of France's CNC, Gaetan Bruel, discusses the country's role in the Oscars, international cinema and ...

But the fitful, often problematic evolution of the community is far from the minds of most as Steamboat holds a certain ...

BOSTON and LONDON, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology ...

Cancer patients who got an mRNA COVID vaccine within a few months of their immunotherapy lived longer than those who did not, health records show.

During BMS’ earnings call Thursday, CEO Chris Boerner, Ph.D., described Cobenfy as “delivering steady growth.” But the first-in-class drug still has a long way to go to fulfill its promise as a ...